Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789611 | 0.86 | EGFR (0.58) | KDM4EEGFRERBB2PTGS2CA2 | |
| SCHEMBL7749432 | 0.85 | MMP2 (0.59) | EGFRERBB2PTGS2NR4A2CA2 | |
| SCHEMBL13954376 | 0.85 | LARS1 (0.60) | EGFRERBB2PTGS2NR4A2LARS1 | |
| SCHEMBL2810873 | 0.85 | EPHX2 (0.55) | KDM4EEGFRERBB2CA2LARS1 | |
| SCHEMBL28399551 | 0.85 | EGFR (0.57) | KDM4EEGFRERBB2PTGS2CA2 | |
| SCHEMBL10993215 | 0.84 | EGFR (0.60) | KDM4EEGFRERBB2PTGS2CA2 | |
| Hydrochloric Acid SCHEMBL5124029 | 0.84 | EPHX2 (0.54) | KDM4EEGFRERBB2CA2LARS1 | |
| SCHEMBL7969578 | 0.83 | EGFR (0.60) | EGFRERBB2PTGS2CA2PTGS1 | |
| SCHEMBL6789607 | 0.82 | EGFR (0.58) | KDM4EEGFRERBB2PTGS2CA2 | |
| SCHEMBL29955409 | 0.82 | ENPP2 (0.50) | EGFRERBB2PTGS2NR4A2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2461683-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-7094903-B2 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | ONCONOVA THERAPEUTICS, INC. (US) | 2006-08-22 | — | — | US | claimed |
| EP-1578721-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED ISOXAZOLES AND 2-ISOXAZOLINES | Onconova Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050143583-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | ONCONOVA THERAPEUTICS, INC. (US) | 2005-06-30 | — | — | US | claimed |
| US-6809204-B2 | HETEROCYCLIC NITROGEN COMPPOUNDS SUCH AS 4-(5-METHYL-3-PHENYL-ISOXAZOL-1-YL)BENZENESULFONAMIDE, USED AS NON-STEROIDAL ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS; CYCLOOXYGENASE INHIBITORS | ONCONOVA THERAPEUTICS, INC. | 2004-10-26 | — | — | US | claimed |
| US-20030162813-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | ONCONOVA THERAPEUTICS, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003031404-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED ISOXAZOLES AND 2-ISOXAZOLINES | ONCONOVA THERAPEUTICS, INC. (US) | 2003-04-17 | — | — | WO | claimed |
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE | 2025-06-19 | — | — | US | disclosed |
| CN-119072467-A | Novel diazapine compounds targeting yellow fever virus non-structural 4B (NS 4B) protein and methods of use thereof | 巴鲁克斯布伦博格研究所 | 2024-12-03 | — | — | CN | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| CN-105330576-B | The phosphate analogs of aryl bicyclic sphingol 1 | 比奥根MA公司 | 2018-04-10 | — | — | CN | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| EP-0411706-B1 | Sulphonamide herbicides | SHELL INT RESEARCH (NL) | 1994-12-07 | — | — | EP | disclosed |
| US-5231072-A | Sulphonamide herbicides | SHELL RESEARCH LIMITED (GB) | 1993-07-27 | — | — | US | disclosed |
| US-5158599-A | SULPHONAMIDE HERBICIDES | SHELL RESEARCH LIMITED (GB) | 1992-10-27 | — | — | US | disclosed |
| US-5024733-A | Palladium alloy electroplating process | AT&T BELL LABORATORIES (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0411706-A1 | Sulphonamide herbicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-02-06 | — | — | EP | disclosed |
| US-3961887-A | Process for the printing of cellulose containing textile material | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | KDM4E 14/4885EGFR 2789/4885ERBB2 2351/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KDM4E 272/4885EGFR 1995/4885ERBB2 1158/4885 |
| US-20050143583-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | F9, HAX1, CYP4X1 | KDM4E 3191/4885EGFR 2032/4885ERBB2 3165/4885 |
| US-20030162813-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | CYP4X1, HAX1, CYCS | KDM4E 2442/4885EGFR 2856/4885ERBB2 3002/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | KDM4E 14/4885EGFR 2789/4885ERBB2 2351/4885 |
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | CUL4B, BRD4, CUL4A | KDM4E 224/4885EGFR 4545/4885ERBB2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.